RNAZ

SCHEDULE 13G - Transcode Therapeutics, Inc. (0001829635) (Subject)

10-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ, the ", Company", )), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.

NT 10-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery. The study was carried out in collaboration with Dr. Anna Moore, Professor, Dire

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, in collaboration with Quantum Leap Healthcare Collaborative (Quantum Leap), today announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational New Drug (IND) application amendment for a planned Phase 2a clinical trial with TransCode's lead therapeutic candidate, TTX-MC138. The study will be conducted by Quantum Leap within their PRE-I-SPY program, a leading platform for innovative oncology clinical trials, and represents the program's first exp

SCHEDULE 13G/A - Transcode Therapeutics, Inc. (0001829635) (Subject)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injectionTTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive glioblastoma modelsStudy supports future clinical development of TTX-MC138 for patients with glioblastomaBOSTON, Jan. 6, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The article was publi

DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K/A - Transcode Therapeutics, Inc. (0001829635) (Filer)

EFFECT - Transcode Therapeutics, Inc. (0001829635) (Filer)

3 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

3 - Transcode Therapeutics, Inc. (0001829635) (Issuer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

S-3 - Transcode Therapeutics, Inc. (0001829635) (Filer)

8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)